The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.
 
Van K. Morris
Consulting or Advisory Role - Array Biopharma; Array Biopharma; Array Biopharma; Array Biopharma; Clinical Genomics; Clinical Genomics; Clinical Genomics; Clinical Genomics
Research Funding - Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma
 
Greg Yothers
Employment - Mountainview Pediatrics (I); Mountainview Pediatrics (I); Mountainview Pediatrics (I); Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics; Orbus Therapeutics; Orbus Therapeutics; Orbus Therapeutics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; MolecularMatch; MolecularMatch; MolecularMatch; Navire; Navire; Navire; Navire
Consulting or Advisory Role - Amal Therapeutics; Amal Therapeutics; Amal Therapeutics; Amal Therapeutics; Amgen; Amgen; Amgen; Amgen; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer Health; Bayer Health; Bayer Health; Bayer Health; Biocartis; Biocartis; Biocartis; Biocartis; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Genentech; Genentech; Genentech; Genentech; Holy Stone Healthcare; Holy Stone Healthcare; Holy Stone Healthcare; Holy Stone Healthcare; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Navire; Navire; Navire; Navire; Novartis; Novartis; Novartis; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Redx Pharma; Redx Pharma; Redx Pharma; Redx Pharma; Roche; Roche; Roche; Roche; Symphogen; Symphogen; Symphogen; Symphogen
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Biocartis (Inst); Biocartis (Inst); Biocartis (Inst); Biocartis (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst)
 
Samuel A. Jacobs
No Relationships to Disclose
 
Peter C. Lucas
Stock and Other Ownership Interests - Amgen; Amgen; Amgen; Amgen
Consulting or Advisory Role - Bayer (I); Bayer (I); Bayer (I); Bayer (I)
 
Atif Iqbal
No Relationships to Disclose
 
Patrick McKay Boland
Honoraria - Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical
Consulting or Advisory Role - Merrimack; Merrimack; Merrimack; Merrimack; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Research Funding - Advaxis (Inst); Advaxis (Inst); Advaxis (Inst); Advaxis (Inst); Athenex (Inst); Athenex (Inst); Athenex (Inst); Athenex (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); Theradiag (Inst); Theradiag (Inst); Theradiag (Inst); Theradiag (Inst)
 
Dustin A. Deming
Consulting or Advisory Role - Acrotech Biopharma; Acrotech Biopharma; Acrotech Biopharma; Acrotech Biopharma; Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Novocure; Novocure; Novocure; Novocure; Promega; Promega; Promega; Promega; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
 
Aaron James Scott
Consulting or Advisory Role - Exelixis; Exelixis; Exelixis; Exelixis
Research Funding - Exelixis; Exelixis; Exelixis; Exelixis; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Genentech; Genentech; Genentech; Genentech; Incyte; Incyte; Incyte; Incyte
Travel, Accommodations, Expenses - Exelixis; Exelixis; Exelixis; Exelixis
 
Howard John Lim
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Merck; Merck; Merck; Merck; Roche Canada; Roche Canada; Roche Canada; Roche Canada; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Eisai; Eisai; Eisai; Eisai; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Norman Wolmark
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); NSABP Foundation (Inst); NSABP Foundation (Inst); NSABP Foundation (Inst); NSABP Foundation (Inst)
Travel, Accommodations, Expenses - Genentech; Genentech; Genentech; Genentech
 
Thomas J. George
Consulting or Advisory Role - Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)